MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
May 13, 2022 at 03:01 am
Share
MYUNGMOON Pharm co.,Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 1,326.52 million compared to KRW 9,877.04 million a year ago. Net income was KRW 965.28 million compared to KRW 617.97 million a year ago. Basic earnings per share from continuing operations was KRW 29 compared to KRW 18 a year ago. Basic earnings per share was KRW 29 compared to KRW 18 a year ago.
MyungMoon Pharm. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The Company is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.
MYUNGMOON PHARM CO.,LTD 